Wondering if anyone with Stage 1 or Stage 2 breast cancer is taking Zometa or Reclast even if they are NOT using aromatase inhibitors (Ais)?
I have stopped taking AIs so at next oncology appointment there will be a discussion if I should also stop the Zometa IVs.
My layman's understanding of why to give Zoledronic acid to patients receiving AIs is that AIs reduces estrogen in body (to prevent recurrence of breast cancer) , but the decreased estrogen levels are associated with elevated rates of osteolysis and the resulting bone loss. Zoledronic acid belongs to a group of drugs called bisphosphonates and those drugs slow down or prevent bone damage.
There is also research that suggested that Zometa also might help stop breast cancer from spreading to the bones by making it harder for breast cancer cells to grow in bones. But my oncologist said it only reduced the risk of breast cancer cells in bone by 1-2% .
My treatment background:
After my treatment for breast cancer (lumpectomy, few positive lymph nodes removed, chemo and radiation) , my oncologist placed me on AIs and Zometa IV every 6 months for 3 years. AIs caused multiple side effects (discussed in other threads on Mayo Connect) so after a year I have stopped taking. So now the question is there a reason or benefit to continue with Zometa if not taking AIs. My next is infusion is due in Oct 2020.
Before making the decision, the dr decided to check my bone density. In 2018, after initial diagnosis and before any treatment a bone density was done. This week it was repeated. I was pleasantly surprised that I had slight improvement in bone density. For a 64 year old post-menopausal women who has undergone breast cancer treatment, anything that showed my bone density is not deteriorating is great news.
Any insight from others on Connect is appreciated.